Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $19.05M (cash outflow) rose 9.3% year over year, ahead of the -757.4% change in trailing-twelve-month change in working capital. Sequentially, it rose 62.1% from the prior quarter.
Context
- Change in working capital amounted to 46.0% of revenue in FY2025, down 10.0 pp from a year earlier.
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.3% holds above the trailing-twelve-month pace of -757.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (79.32M) USD
- Year-over-year change
- -697.7%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (79.32M) | -697.7% |
| FY2024 | 2024-12-31 | 13.27M | -58.3% |
| FY2023 | 2023-12-31 | 31.86M | +1823.9% |
| FY2022 | 2022-12-31 | 1.66M | +117.3% |
| FY2021 | 2021-12-31 | (9.6M) | — |
Change in Working Capital vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's LTM Mar 2026 change in working capital of $80.94M is the 3rd largest of the 11 companies compared; the peer median is $3.45M.
- Its year-over-year change of -757.4% is the lowest of 11, against a peer median of -48.2%.
- Change in working capital amounts to 37.3% of revenue for SNDX, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $226.65M | +499.3% | +23.2% | 85.2% | |
| LTM Jun 2026 | $87M | -18.7% | — | 74.4% | |
| LTM Mar 2026 | $80.94M | -757.4% | — | 37.3% | |
| LTM Aug 2026 | $50.82M | +271.7% | +18.4% | 7.2% | |
| LTM Mar 2026 | $29.7M | -77.6% | +30.8% | 83.6% | |
| LTM Mar 2026 | $17.87M | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | $3.95M | +22.3% | -67.6% | — | |
| LTM Jun 2026 | $2.95M | -350.5% | +51.5% | 1.7% | |
| LTM Jun 2026 | $2.5M | -91.4% | -1.0% | 2.4% | |
| LTM Dec 2025 | $2.34M | -78.5% | +49.3% | — | |
| LTM Mar 2026 | $974K | -159.1% | +130.6% | — | |
| Peer median (excluding SNDX) | $3.45M | -48.2% | +30.8% | 11.4% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 24.93M | (149.34M) | (209.36M) | (318.76M) | (285.42M) |
| Depreciation & Amortization | 43K | 33K | 12K | 8K | 6K |
| Deferred Income Tax | 255K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.32M | 16.02M | 30.95M | 43.03M | 47.5M |
| Change in Working Capital | (9.6M) | 1.66M | 31.86M | 13.27M | (79.32M) |
| Accounts Receivables | 0 | (3.47M) | 10.71M | (11.24M) | (36.83M) |
| Inventory | 0 | 3.47M | 0 | (366K) | (32.09M) |
| Accounts Payables | 2.16M | (1.32M) | 5.61M | 1.67M | 4.95M |
| Other Working Capital | (11.76M) | 2.98M | 15.54M | 23.21M | (15.35M) |
| Other Non-Cash Items | 187K | (2.05M) | (14.06M) | (12.45M) | (5.75M) |
| Operating Cash Flow | 29.13M | (133.68M) | (160.6M) | (274.9M) | (322.98M) |
| Capital Expenditures | (129K) | (225K) | 0 | 0 | (187K) |
| Acquisitions (Net) | 40.74K | 225K | 0 | 0 | 0 |
| Purchases of Investments | (294.72M) | (495.35M) | (354.61M) | (557.05M) | (195.81M) |
| Sales of Investments | 253.98M | 308.93M | 472.22M | 337.28M | 486.03M |
| Other Investing Activities | (40.74K) | 225K | 0 | 0 | 0 |
| Investing Cash Flow | (40.87M) | (186.19M) | 117.61M | (219.78M) | 290.04M |
| Debt Repayment | 0 | (21M) | 0 | 0 | 0 |
| Common Stock Issued | 86.34M | 181.39M | 258.09M | 9.72M | 13.68M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 32.13M | 11.86M | 6.04M | 343.65M | 0 |
| Financing Cash Flow | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 106.72M | (147.61M) | 221.14M | (141.31M) | (19.27M) |
| Free Cash Flow | 29M | (133.9M) | (160.6M) | (274.9M) | (323.17M) |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.